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clinical case report
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E449X Mutation in the Thyroid Hormone Receptor β 
Associated with Autoimmune Thyroid Disease and Severe 
Neuropsychomotor Involvement
ABSTRACT
Objective: To report the clinical and molecular aspects of a patient with a 
diagnosis of Resistance to Thyroid Hormone (RTH) harboring the E449X 
mutation associated with autoimmune thyroid disease and severe neurop-
sychomotor retardation. Methods: We present a case report including clini-
cal and laboratory fi ndings, and molecular analysis of a Brazilian patient 
with RTH. Results: A 23-year old male presented hyperactivity disorder, at-
tention defi cit, delayed neuropsychomotor development, and goiter. Since 
the age of 1 year and 8 months, his mother had sought medical care for her 
son for the investigation of delayed neuropsychomotor development asso-
ciated with irritability, aggressiveness, recurrent headache, profuse sudo-
resis, intermittent diarrhea, polyphagia, goiter, and low weight. Laboratory 
tests revealed normal TSH, increased T3, T4, antithyroglobulin and antimi-
crosomal antibody titers. Increasing doses of levothyroxine were prescribed, 
reaching 200 µg/day, without signifi cant changes in his clinical-laboratory 
picture. Increasing doses of tiratricol were introduced, with a clear clinical 
improvement of aggressiveness, hyperactivity, tremor of the extremities, 
and greater weight gain. Molecular study revealed a nonsense mutation in 
exon 10, in which a substitution of a guanine to tyrosine in nucleotide 1345 
(codon 449) generates the stop codon TAA, confi rming the diagnosis of RTH. 
Conclusion: This patient has severe neuropsychomotor retardation not ob-
served in a single previous report with the same mutation. This may refl ect 
the lack of a genotype-phenotype correlation in affected cases with this syn-
drome, suggesting that genetic variability of factors other than β receptor of 
thyroid hormone (TRβ) might modulate the phenotype of RTH. (Arq Bras 
Endocrinol Metab 2008; 52/8:1203-1210)
Keywords: Resistance to Thyroid Hormone; TRβ gene; E449X Mutation; Auto-
immune; Thyroid Disease; Retarded Neuropsychomotor Development 
RESUMO
Mutação E449X no Receptor β do Hormônio Tireoidiano Associada com 
Doença Tireoidiana Auto-Imune e Retardo Neuropscicomotor Grave.
Objetivos: Descrever aspectos clínicos e moleculares de um paciente com 
resistência ao hormônio tireoidiano (RHT) portador da mutação E449X asso-
ciada a doença tireoideana auto-imune e retardo neuropscicomotor grave. 
Métodos: Relatamos um caso incluindo achados clínicos, laboratoriais e aná-
lise molecular de um paciente brasileiro com RHT. Resultados: Paciente mas-
culino, 23 anos de idade, apresentou-se com distúrbio de hiperatividade, 
défi cit de atenção, retardo no desenvolvimento neuropsicomotor e bócio. 
Desde 1 ano e 8 meses de idade, sua mãe procurou assistência médica para 
investigação do retardo do desenvolvimento neuropsicomotor associado 
com irritabilidade, agressividade, cefaléia recorrente, sudorese profusa, diar-
réia intermitente, polifagia, bócio e perda de peso. Avaliação laboratorial evi-
denciou TSH normal e aumento do T3, T4 e anticorpos antimicrossomal e 
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antitireoglobulina. Doses crescentes de levotiroxina foram prescritas, máxi-
mo de 200 µg/dia, sem signifi cativas alterações em seu quadro clínico-labora-
torial. Doses crescentes de tiratricol foram introduzidas com melhora clínica 
evidente da agressividade, da hiperatividade, do tremor de extremidades e 
maior ganho de peso. O estudo molecular revelou uma mutação nonsense 
no éxon 10, no qual a substituição da guanina pela tirosina no nucleotídeo 
1345 (códon 449) gerou um stop códon TAA, confi rmando o diagnóstico da 
RHT. Conclusão: Este paciente tem um grave retardo neuropiscomotor não 
observado em um relato único anterior com a mesma mutação. Isto pode 
refl etir a falta de relação genotipo-fenótipo nos casos afetados com esta sín-
drome sugerindo que a variabilidade genética de outros fatores, além do re-
ceptor do hormônio tireoidiano (HT), possa modular o fenótipo da RHT. (Arq 
Bras Endocrinol Metab 2008; 52/8:1203-1210)
Descritores: Resistência ao hormônio tireoidiano; gene TRβ; Mutação E449X; 
Doença tireoideana auto-imune; Desenvolvimento neuropsicomotor retardado
INTRODUCTION
The resistance to thyroid hormone (RTH) syndrome was fi rst described by Samuel Refetoff and cols., in 
1967 (1). Several cases were later reported, most of them 
involving clinically euthyroid patients, whereas other in-
volved patients with signs and symptoms of hypothy-
roidism and/or thyrotoxicosis. These were associated 
with biochemical changes such as elevated thyroid hor-
mone (TH) levels - T3 and T4, and inappropriately nor-
mal or elevated thyroid stimulating hormone (TSH) 
levels, demonstrating tissue insensitivity to the action of 
these hormones. The most common pattern of inheri-
tance is autosomal dominant, but there are also reports 
of a recessive pattern and of sporadic and de novo cases. 
The disease has been more frequently associated with 
heterozygous mutations of the β receptor of TH (TRβ) 
(2,3). More than 1000 cases belonging to 344 different 
families have been reported thus far, involving approxi-
mately 124 mutations, with missense mutations being 
more frequent (4). There are no pathognomonic clinical 
fi ndings for RTH because, due to the variable resistance 
of different tissues, symptoms of hypothyroidism such as 
inadequate weight-height development, delayed bone 
age and mental retardation may coexist with symptoms 
of hyperthyroidism such as attention defi cit, tachycardia 
and hyperactivity (2). Several studies have discussed 
whether the severity of the clinical manifestations of pa-
tients with RTH is correlated with the degree of func-
tional impairment of the mutated receptor (5). 
There is no currently specifi c treatment for the cor-
rection of the primary defect of RTH (2). In most of 
the cases described, untreated patients maintain a nor-
mal metabolic status, whereas some patients with more 
marked peripheral resistance require supraphysiological 
doses of TH (2).
Although more than 1000 cases of RTH have been 
reported in the world literature, coexistence of autoim-
mune thyroid disease has been seldom reported. Sato 
and cols. (6) reported that patients with RTH in gene-
ral have no antithyroglobulin or antithyroperoxidase 
antibodies, excepting rare cases in which there is coe-
xistence of chronic autoimmune thyroiditis.
We report here a 23-year-old male patient with au-
toimmune thyroid disease and RTH due to a nonsense 
mutation, in which a substitution of a guanine to tyrosine 
in nucleotide 1345 (codon 449) generated the stop co-
don TAA. The patient presented severe neuropsychomo-
tor manifestations, a clinical picture that has not been 
previously reported in association with this mutation (7). 
SUBJECTS AND METHODOS
Case report
A 23-year old mulatto male born to non-consanguineous 
parents, according to his mother, presented hyperactivity 
disorder, attention defi cit, delayed neuropsychomotor de-
velopment, and goiter. Since the age of 1 year and 8 mon-
ths, the mother had sought medical care for her son for 
the investigation of delayed neuropsychomotor develop-
ment associated with irritability, aggressiveness, recurrent 
headache, profuse sudoresis, intermittent diarrhea, poly-
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phagia, increased cervical volume, and low weight. The 
patient had been born at term by normal delivery with 
cyanosis, weighing 2300 g and measuring 47 cm. Howe-
ver, he had not needed intensive supportive care and had 
been discharged from the hospital within 48 hours. No 
neonatal screening test was performed. He presented de-
layed neuropsychomotor development, sitting up at 1 
year, walking at 3 years and speaking at 4 years. The mo-
ther denied prenatal problems or a similar history among 
family members. 
At his fi rst evaluation at 5 years of age, the patient 
presented hyperactivity and irritability, weight and 
height in the 3rd and 50th percentiles, respectively, 
diffuse increase in thyroid volume (approximately 2 to 
3 times) without exophthalmia, and tachycardia at 
rest (heart rate of 120 bpm). Psychodiagnostic evalu-
ation revealed a high degree of impairment of cogni-
tive aptitudes and of social-motor language associated 
with a low level of visuomotor coordination. Labora-
tory tests at 5 years of age revealed total T3 >580 ng/
Table 1. Laboratory profi le of a patient with thyroid hormone resistance without and during treatment with methimazole (Tapa-
zol®) and after the administration of 131Iodine followed by replacement with levothyroxine and tiratricol (Triac®).
Patient age
(years old)
Treatment
T3 (ng/dL) T4 (µg/dL)/
*FreeT4 (ng/dL) 
TSH (µIU/mL)
5 None 580.0 23.2 3.5
5.3 TPZ – 30mg >800.0 >30.0 4.5 
6 TPZ – 30mg 84.0 36.0 1.3
12 Administration of 131Iodine
14
15
16
17
18
19
LT4 (150µg)
LT4 (150µg)
LT4 (150µg)
LT4 (200µg)
LT4 (200µg)
LT4 (100µg) + Triac® (75µg/d)
–
–
–
–
–
168.9
2.5*
1.69*
1.23*
1.64*
1.94*
1.5*
>50.0
134.0
>60.0
>60.0
69.4
56.1
20 LT4 (100µg) 92.8 1.2* 74.3
21 LT4 (200µg) + Triac® (50µg/d) 151.8 3.5* 45.0
22 LT4 (150µg) + Triac® (100µg/d) 130.0 1.7* 65.5
23
23.4
LT4 (200µg) + Triac® (150µg/d)
LT4 (150µg) + Triac® (200µg/d)
150.5
158.9
2.2*
3.05*
>100.0
>40.0
TPZ = Tapazol® (methimazole); Triac® (tiratricol); LT4 (levothyroxine); - : not available; Reference Values: T3: 90-200 ng/dL; T4 : 4.5-12.5 µg/dL; Free T4: 0.71-1.85 ng/dL; TSH: 
0.3-3.0 µIU/mL
dl (reference value: 90-200 ng/dl), total T4 23.2 µg/
dl (reference value: 4.5-12.5 µg/dl), and TSH:3.5 
µIU/ml (reference value: 0.3-3.0 µIU/ml), anti-
thyroglobulin antibody titers: 1:400, and antimicro-
somal antibody titers of: 1:25,600. 
Methimazole (Tapazol®) up to 30 mg/day and 
propranolol (30 mg/day) were started by the oral rou-
te without a signifi cant clinical improvement, except 
for reduction of tremor and irritability, with persistence 
of weight defi cit, hyperkinesia and emotional lability, 
tachycardia and goiter. Laboratory evaluations during 
the subsequent six years of treatment revealed persis-
tently elevated levels of total T3 and T4 and inappro-
priately normal TSH (Table 1). Thyroid scintigraphy 
with 99mTc--pertechnetate demonstrated a marked in-
crease in gland volume, especially the right lobe, with 
globally increased uptake (79% within 24 hours) and 
slightly heterogeneous distribution. At the age of 12, 
he was submitted to radioiodine therapy with 15 mCi 
of 131I. In view of no resolution of symptoms and 
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signs, the patient was investigated for the exclusion of a 
TSH-secreting pituitary tumor (thyrotrophinoma). 
The TSH response to intravenous TRH administration 
was higher than 40 µIU/ml at all time points. The level 
of the α subunit of TSH was 0.47 mIU/ml (VR<0.8 
mIU/ml). Futhermore, the evaluation of the hypota-
lhalamic-pituitary axis conducted with magnetic reso-
nance imaging (MRI) didn’t reveal any abnormality. 
Increasing doses of levothyroxine were prescribed, 
reaching 200 µg/day, without signifi cant changes in 
the clinical-laboratory picture of the patient. Increasing 
doses of tiratricol (Triac® 50, 75, 100, 150, 200 µg/
day) were introduced (Table 1), an option that also did 
not result in TSH suppression but induced a clear clini-
cal improvement of aggressiveness, hyperactivity, tre-
mor of the extremities, and greater weight gain (8,9). 
At present he is regularly taking 200 µg/day tiratricol 
and 150 µg/day levothyroxine, no longer presenting 
signs or symptoms of hyper- or hypothyroidism, and 
his heart rate is 70 bpm. His height is 163.5 cm (SD = 
-0.9), his weight is 49.5 kg and his pubertal develop-
ment is normal (G5 P5). He attends a special school for 
children with severe cognitive defi cit. He cannot read 
or write but is able to execute domestic tasks. 
A molecular study of this patient was recently per-
formed by genomic extraction of peripheral blood 
DNA using a previously described method (3). The 
study revealed a nonsense mutation in exon 10, in whi-
ch a substitution of a guanine to tyrosine in nucleotide 
1345 (codon 449) generates the stop codon TAA, con-
fi rming the diagnosis of RTH (Figure 1).
DISCUSSION
We report here a Brazilian patient with severe neurop-
sychomotor retardation and RTH due to the c.1345G>T 
mutation. In Brazil, Furlanetto and cols. (10) made the 
fi rst report concerning the genetic study of the TRβ. 
Recently, Magalhães and cols. (3) described the geno-
typic analysis of four unrelated kindreds from the Ri-
beirão Preto (SP) region, representing the largest 
Brazilian series published. 
We report a patient who had been presenting clini-
cal characteristics attributable to RTH since early in-
fancy. Low birth weight as well as delayed bone 
maturation from the prenatal period to adult life are 
due to the reduced affi nity of TH for the ligand domain 
of TRβ, mimicking a state of hypothyroidism (2). Up 
to 30% of children with RTH have low weight for their 
age and very low weight for height (3), as was observed 
in the present patient, whose weight and height were in 
the 3rd and 50th percentile, respectively. Attention de-
fi cit and hyperactivity, the major symptoms that led the 
present patient to seek medical care, have been explai-
ned by a possible action of TH on the development of 
central monoaminergic pathways (11). Tachycardia and 
goiter, also observed in the present case, are common 
fi ndings frequently acting as confounding diagnostic 
factors since they mimic the signs and symptoms of 
thyrotoxicosis (2,3). Varied degrees of attention defi cit 
or learning disorders may be detected in up to 50% of 
cases. However, severe neuropsychomotor retardation, 
as observed in the present patient, is uncommon, being 
detected in approximately 4-16% of the cases (12). To 
the best of our knowledge the present case is the fi rst 
description of E449X nonsense mutation with this phe-
notype described here. Miyoshi and cols. (13) identi-
fi ed three truncated TRβ1s with 11 (F451X), 13 
(E449X) and 16 (C446X) amino acids deletions within 
this domain in patients with RTH but only the patients 
harboring a C-terminal truncated receptor, F451X and 
C446X, exhibited severe mental retardation. Phillips 
and cols (14) also described a patient with severe phe-
notype including severe mental retardation with a TRβ 
truncation mutant, R438Xfs. Transient expression stu-
dy revealed that these mutants had negligible T3 bin-
ding and transcriptional activities (13). 
The laboratory work-up described here correspon-
ds to the characteristic pattern of RTH, i.e., an inap-
propriately normal TSH level and elevated free T4 and 
total T3 levels (12). As mentioned in previous studies 
Figure 1. Representative (anti-sense) chromatogram of exon 
10 of gene β of the thyroid hormone receptor in a patient 
with resistance to thyroid hormone, showing the c.1345G>T 
(p.E449X) mutation in heterozygosis. The arrow indicates the 
position of the mutation.
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(3), an erroneous diagnosis of thyrotoxicosis is not in-
frequent, as was initially the case for the patient repor-
ted here. The high thyroid iodine uptake described 
(79% in 24 h), associated with clinical signs and symp-
toms compatible with thyrotoxicosis, and frequently 
leads to erroneous treatment with antithyroid drugs 
and/or radioactive iodine.
Although it is an important differential diagnosis, 
the determination of subunit α, associated with the ab-
sence of characteristic pituitary damage, excluded the 
possible presence of thyrotropinomas. The present pa-
tient had high antithyroid antibody titers (1:400 for 
antithyroglobulin antibodies and 1:25,600 for antimi-
crosomal antibodies), an infrequent fi nding in previous 
reports. Search for heterophilic antibodies was not per-
formed, once the mutation E449X was found. Sato and 
cols. (6) reported that RTH is not associated with the 
presence of antithyroid antibodies except in rare ca-
ses in which autoimmune thyroiditis coexists. Gavin 
and cols. (15) raised the hypothesis that the chronic 
TSH elevation occurring in RTH syndrome may sti-
mulate lymphocytes to produce antibodies against 
the TH receptor.
It has been previously demonstrated that, despite 
the excess TH, most patients continue to be euthyroid, 
probably due to adequate compensation for the increa-
se in endogenous TH, with no need for treatment (2). 
However, some individuals have more resistant peri-
pheral tissues, requiring supraphysiological doses of 
TH (2). Treatment of the present patient with tiratricol 
improved the symptoms of hyperactivity and atten-
tion defi cit and reduced the goiter without an in-
crease of thyromimetic effects on peripheral tissues, 
a fact that can be explained by a greater affi nity of 
this drug for TRβ.
The genetic study conducted on this patient iden-
tifi ed a nonsense mutation in exon 10, in which a subs-
titution of a guanine to tyrosine in nucleotide 1345 
(codon 449) generated the TAA stop codon and a 
truncated protein with 13 amino acids missing. There 
is only one previous report of this mutation, published 
by Taniyama and cols. (7) in 1996, affecting a eumeta-
bolic 16-year-old Japanese boy with elevated TH levels 
and with a mild form of clinical involvement. In con-
trast, in the case reported here the patient presented 
severe neuropsychomotor impairment, refl ecting a 
more severe spectrum of phenotypic expression.This 
fact confi rms the variability of the phenotype associated 
with a specifi c genotype in RTH syndrome, supporting 
the absence of a clear correlation between the clinical 
severity of RTH and the degree of functional failure of 
TRβ (5). 
In conclusion, the present report describes a rare 
case of RTH with a nonsense mutation in exon 10, in 
which a substitution of a guanine to tyrosine in nucle-
otide 1345 (codon 449) generated the stop codon 
TAA. This mutation is associated with autoimmune 
thyroid disease and with severe neuropsychomotor in-
volvement, a clinical picture not previously described in 
association with this genotype, suggesting once more 
the phenotypic diversity of patients with mutations in 
the TRβ gene.
No potential confl ict of interest relevant to this article was re-
ported.
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